Louisiana prisoners to get non-FDA-approved BioCorRx implant

BioCorRx (OTC:BICX) has begun a controversial pilot program to provide soon-to-be-released Louisiana prison inmates an opioid addiction treatment implant that has not been approved by the FDA.

The pilot, announced last week, has drawn praise from corrections officials and concern from prisoner advocates and some medical professionals, according to a report in The Advocate, a Baton Rouge, La. newspaper.

Ten inmates who volunteer for the program and are approved by prison medical staff will participate in the company’s BioCorRx recovery program, which typically includes its proprietary cognitive behavioral therapy, peer support, the BICX102 multi-month sustained-release naltrexone implant and patient tracking, the Anaheim, Calif.-based company said.

Get the full story on our sister site, Drug Delivery Business.